{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(11)"],"submitter":["Dunn LK"],"pubmed_abstract":["<h4>Background</h4>Patients with spontaneous and traumatic intracranial hemorrhage (ICH) are frequently transfused platelets to treat thrombocytopenia, platelet function defects, and reverse antiplatelet drugs. ABO-identical platelet transfusion has been suggested to lead to higher post-transfusion platelet increments compared to major-ABO incompatible transfusion. We hypothesized that patients who received ABO-identical transfusion would have higher post-transfusion platelet increments and superior neurologic outcomes.<h4>Methods</h4>Adults with traumatic or non-traumatic ICH from January 1st 2018 to December 31st 2022 were identified using electronic medical records and international classification of disease (ICD)-10 codes. Patients were excluded if they lacked a platelet count within 24 hours before and within 24 hours after transfusion or if they received multiple platelet transfusions before their platelet count was remeasured. After stratification by ABO-identical, ABO-major incompatible, and ABO-minor incompatible transfusion, post transfusion increments were compared, as were clinical outcomes.<h4>Results</h4>Among 167 patients who received platelet transfusion, 76 (45.5%) received ABO-identical transfusion, 54 (32.3%) received ABO-major incompatible transfusion, and 37 (22.2%) received ABO-minor incompatible transfusion. There were no significant differences in absolute platelet increment between groups. The median increment was 7x109/L for ABO-identical platelets, 10x109/L for ABO-major incompatible platelets, and 11x109/L for ABO-minor incompatible platelets, p = .87. There was no significant difference in the percentage of patients discharged alive with modified Rankin score of 1 or 2 or cerebral performance category 1 or 2 between groups (p = .56 and .39 respectively). After adjusting for confounders in a general linear model there remained no associations between ABO compatibility and platelet increment after transfusion.<h4>Conclusions</h4>Our data support similar efficacy for ABO-identical and ABO-incompatible platelet transfusion in patients with ICH."],"journal":["PloS one"],"pagination":["e0312602"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11581237"],"repository":["biostudies-literature"],"pubmed_title":["ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage."],"pmcid":["PMC11581237"],"pubmed_authors":["Holley Z","Dunn LK","Trejo JP","Naik BI","Khan J","Mazzeffi M","Venner E","Nguyen M"],"additional_accession":[]},"is_claimable":false,"name":"ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage.","description":"<h4>Background</h4>Patients with spontaneous and traumatic intracranial hemorrhage (ICH) are frequently transfused platelets to treat thrombocytopenia, platelet function defects, and reverse antiplatelet drugs. ABO-identical platelet transfusion has been suggested to lead to higher post-transfusion platelet increments compared to major-ABO incompatible transfusion. We hypothesized that patients who received ABO-identical transfusion would have higher post-transfusion platelet increments and superior neurologic outcomes.<h4>Methods</h4>Adults with traumatic or non-traumatic ICH from January 1st 2018 to December 31st 2022 were identified using electronic medical records and international classification of disease (ICD)-10 codes. Patients were excluded if they lacked a platelet count within 24 hours before and within 24 hours after transfusion or if they received multiple platelet transfusions before their platelet count was remeasured. After stratification by ABO-identical, ABO-major incompatible, and ABO-minor incompatible transfusion, post transfusion increments were compared, as were clinical outcomes.<h4>Results</h4>Among 167 patients who received platelet transfusion, 76 (45.5%) received ABO-identical transfusion, 54 (32.3%) received ABO-major incompatible transfusion, and 37 (22.2%) received ABO-minor incompatible transfusion. There were no significant differences in absolute platelet increment between groups. The median increment was 7x109/L for ABO-identical platelets, 10x109/L for ABO-major incompatible platelets, and 11x109/L for ABO-minor incompatible platelets, p = .87. There was no significant difference in the percentage of patients discharged alive with modified Rankin score of 1 or 2 or cerebral performance category 1 or 2 between groups (p = .56 and .39 respectively). After adjusting for confounders in a general linear model there remained no associations between ABO compatibility and platelet increment after transfusion.<h4>Conclusions</h4>Our data support similar efficacy for ABO-identical and ABO-incompatible platelet transfusion in patients with ICH.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T01:21:04.041Z","creation":"2025-04-04T01:21:04.041Z"},"accession":"S-EPMC11581237","cross_references":{"pubmed":["39570940"],"doi":["10.1371/journal.pone.0312602"]}}